SecBot SecBot
DEFA14A ·Filed Apr 27, 2026

MRVI

MARAVAI LIFESCIENCES HOLDINGS, INC.
NEUTRAL
Impact 1/10
Horizonimmediate Processed6mo ago SEC0001823239-26-000016
Proxy solicitation materials
Actionable Insight • Neutral

No trading action warranted. This is a purely technical correction to add XBRL tagging. Monitor the actual Annual Meeting on May 26, 2026, for voting outcomes, but no market-moving information is expected from this filing.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.56
T+0 close · Apr 28, 2026 · via day close
Latest settled
+98.03%
T+60 · $7.05
Vs SPY
+94.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 28 $3.56entry
  2. T+1 · 7mo ago −2.25%α −2.24% · $3.48
  3. T+5 · 7mo ago +8.15%α +6.45% · $3.85
  4. T+20 · 6mo ago +22.75%α +17.30% · $4.37
  5. T+60 · 4mo ago +98.03%α +94.04% · $7.05

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Maravai LifeSciences Holdings, Inc. filed a DEFA14A to add Inline XBRL tagging to its definitive proxy statement for the 2026 Annual Meeting of Shareholders, correcting an inadvertent omission. The proxy statement covers the election of three Class III directors (Bernd Brust, Gregory T. Lucier, Luke Marker), ratification of Deloitte & Touche LLP as auditor, and an advisory say-on-pay vote. The filing is purely administrative and contains no new material information.

Key Financial Metrics

Vote
director election
Meeting
2026-05-26

Key Facts

  • DEFA14A filed solely to add Inline XBRL tagging omitted from original proxy statement
  • No modifications or updates to any disclosures in the original proxy statement
  • Annual Meeting scheduled for May 26, 2026, at 2:30 p.m. Pacific Time, virtual-only format
  • Record date for voting is March 27, 2026
  • Proposals include election of three Class III directors, ratification of Deloitte & Touche LLP, and advisory say-on-pay vote
  • GTCR controls majority of outstanding common stock and has director nomination rights

Financial Impact

No financial impact, filing is administrative correction only

Risk Factors

  • No material risks identified from this administrative filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
59% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001823239-26-000016
Document: 0001823239-26-000016-index-headers.html0001823239-26-000016
Document: 0001823239-26-000016-index.html0001823239-26-000016
Document: 0001823239-26-000016.txt0001823239-26-000016

Track record

5 reports on MRVI

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Sep 29, 20266w ago SC 13G Neutral 4/10 Entry $7.66 Now $7.40 −3.39% settles Dec 24
  2. Jun 14, 202622w ago Institutional Cluster Mixed 4/10 Entry $4.96 to $6.95 Now $7.40 +49.19% ▲ +40.12% +39.12% vs SPY
  3. Jun 3, 202623w ago 8-K Bullish 6/10 Entry $4.84 to $8.37 Now $7.40 +52.89% ▲ +72.93% +70.44% vs SPY
  4. Apr 27, 202629w ago DEFA14A Neutral 1/10 Viewing Entry $3.56 to $7.05 Now $7.40 +107.87% ▲ +98.03% +94.04% vs SPY
  5. Feb 26, 202637w ago 8-K Mixed 6/10 Entry $3.56 to $4.40 Now $7.40 +107.87% ▲ +23.60% +15.42% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens in 5h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 28, 2026